A generic formulation of Zeposia (ozanimod), which won tentative approval for treating multiple sclerosis (MS) from the U.S. Food and Drug Administration (FDA), will be manufactured and supplied by Synthon, based in the Netherlands. Tentative approval means the generic version has met all FDA requirements for…
Read more
At a recent social gathering, my military career came up, including the more than 100 parachute jumps I’ve done in my life. As usual, someone remarked that I must have enjoyed parachuting, and I had to say that I didn’t because I was actually afraid of heights. That brought the…
TG Therapeutics has started enrolling participants in a Phase 3 trial to test a new version of Briumvi (ublituximab-xiiy) that can be injected at home. This change could offer greater convenience and flexibility for people with relapsing forms of multiple sclerosis (MS). The new formulation is given…
Immunic Therapeutics will receive a new U.S. patent covering its experimental therapy, vidofludimus calcium, and some related molecules in people with multiple sclerosis (MS). Titled “Treatment of multiple sclerosis comprising DHODH inhibitors,” the patent explicitly covers the use of the molecules in progressive types of MS, including primary…
We all have stomach or bathroom issues from time to time. Eat the wrong thing, catch a bug, drink too much coffee, and your body will let you know. That’s just life. But when you have multiple sclerosis (MS), digestive and urinary problems aren’t occasional; they become their own…
Get regular updates to your inbox.
